A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.

@article{Sehouli2002API,
  title={A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.},
  author={Jalid Sehouli and Dirk Stengel and G{\"u}lten Oskay and Oumar Camara and H. J. Hindenburg and Peter Klare and Jens Uwe Blohmer and Georg Heinrich and Dirk Elling and Peter Ledwon and Werner Lichtenegger},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2002},
  volume={13 11},
  pages={1749-55}
}
BACKGROUND Second-line chemotherapy for patients with ovarian cancer who failed platinum and paclitaxel treatment remains a therapeutic challenge. We investigated the toxicity profile and therapeutic efficacy of a novel combination regimen, topotecan plus gemcitabine, in a clinical phase II study. PATIENTS AND METHODS Women with relapsed epithelial ovarian cancer after platinum and paclitaxel treatment were eligible to participate in this trial. Topotecan was given at an initial dose of 0.5… CONTINUE READING